SEC Form 10-Q filed by Kodiak Sciences Inc
$KOD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2025 | $24.00 | Neutral → Buy | H.C. Wainwright |
| 10/24/2025 | $24.00 | Neutral → Overweight | Analyst |
| 9/25/2025 | $17.00 | Underweight → Equal Weight | Barclays |
| 9/22/2025 | $15.00 | Buy | Jefferies |
| 8/14/2025 | $15.00 | Underweight → Neutral | Analyst |
| 12/9/2024 | $20.00 | Hold → Buy | Jefferies |
| 9/5/2024 | $3.00 | Neutral | H.C. Wainwright |
| 12/11/2023 | $2.00 | Sell | Goldman |
PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusiasm...across all three of our late-stage programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "Looking ahead, we expect this momentum to continue building as we enter an action-packed 2026 with all three of our Phase 3 assets on track for Phase 3 topline data readouts as well as our first planned BLA filing. On top of
PALO ALTO, Calif., Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies Global Healthcare Conference in London, UK Date: Monday, November 17, 2025Time: 4:30pm GMT (8:30am PST)Format: Presentation8th Annual Evercore Healthcare Conference in Coral Gables, FloridaDate: Wednesday, December 3, 2025Time: 3:00pm EST (12pm PST)Format: Fireside chatA live webcast of both presentations will be available on the "Eve
Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving improvement of 3-lines or more on the eye chart (≥15 letter gain).≥90% of patients in the top two dose levels achieved and sustained real dryness of the retina, as demonstrated by absence of intraretinal fluid (IRF) as well as subretinal fluid (SRF), key markers of disease activity.The Phase 3 PEAK and PINNACLE studies of KSI-101 are enrolling at a faster-than-expected pace, evaluating the top two dose levels (5 mg and 10 mg) in patients with MESI.PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Kodia
H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00
Analyst upgraded Kodiak Sciences from Neutral to Overweight and set a new price target of $24.00
Barclays upgraded Kodiak Sciences from Underweight to Equal Weight and set a new price target of $17.00
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
SCHEDULE 13G - Kodiak Sciences Inc. (0001468748) (Subject)
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)